Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Wynne

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
The Pediatric Infectious Disease Journal|November 21, 2002
Multinational study of pneumococcal serotypes causing acute otitis media in childrenWilliam P Hausdorff, Greg Yothers, Ron Dagan, et al.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
AIDS Research and Therapy|March 22, 2024
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studiesSharon Walmsley, Don E Smith, Miguel Górgolas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialJosep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
AIDS and Behavior|September 3, 2024
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA StudyPrincy Kumar, Amanda E Clarke, Celia Jonsson-Oldenbüttel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
The Pediatric Infectious Disease Journal|November 21, 2002
Multinational study of pneumococcal serotypes causing acute otitis media in childrenWilliam P Hausdorff, Greg Yothers, Ron Dagan, et al.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
AIDS Research and Therapy|March 22, 2024
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studiesSharon Walmsley, Don E Smith, Miguel Górgolas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialJosep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
AIDS and Behavior|September 3, 2024
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA StudyPrincy Kumar, Amanda E Clarke, Celia Jonsson-Oldenbüttel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Pageof 8